MedWorm: Docetaxel

  Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate [Genitourinary Cancer]

Conclusion Abiraterone acetate has significant antitumor activity in post-docetaxel patients with CRPC. Randomized, phase III trials of abiraterone acetate are underway to define the future role of this agent. (Source: Journal of Clinical Oncology)

top  

  Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer [Genitourinary Cancer]

Conclusion AA plus prednisone was well tolerated, with encouraging antitumor activity in heavily pretreated CRPC patients. The incidence of mineralocorticoid-related toxicities (hypertension or hypokalemia) was reduced by adding low-dose prednisone. The combination of AA plus prednisone is recommended for phase III investigations. (Source: Journal of Clinical Oncology)

top  

  Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer.

Authors: O'Brien C, True LD, Higano CS, Rademacher BL, Garzotto M, Beer TM Clinical trials are evaluating the effect of neoadjuvant chemotherapy on men with high-risk prostate cancer. Little is known about the clinical significance of postchemotherapy tumor histopathologic features. We assessed the prognostic and predictive value of histologic features (intraductal carcinoma, vacuolated cell morphologic features, inconspicuous glands, cribriform architecture, and inconspicuous cancer cells) observed in 50 high-risk prostate cancers treated with preprostatectomy docetaxel and mitoxantrone. At a median follow-up of 65 months, the overall relapse-free survival (RFS) rates at 2 and 5 years were 65% and 49%, respectively. In univariate analyses (using the Kaplan-Meier method and log-rank te...

top  

  Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer

The objective of the current review was to evaluate the effects of chemotherapy on the HRQoL of patients with metastatic or locally advanced, inoperable esophagogastric cancer.A systematic MEDLINE search was performed to address a predefined question list: Does chemotherapy improve or maintain HRQoL? Do available data favor a particular chemotherapy? What relation exists between HRQoL and the efficacy and tolerability of therapy?The majority of studies, including large randomized studies, indicated no significant improvements in mean HRQoL scores versus baseline after chemotherapy. However, scores were maintained and symptomatic relief or improved performance status was observed in many patients. HRQoL was maintained in approximately 50% of patients for up to 6 months but deteriorated in t...

top  

  Beyond the Abstract - A pharmacogenetic study of docetaxel and thalidomide in patients with ...

BERKELEY, CA (UroToday.com) - Docetaxel is the current standard of care for men with recurrent castrate resistant prostate cancer (CRPC)... (Source: UroToday)

top  

  Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma

Conclusion  This sequential treatment is feasible with a favourable safety profile and produced encouraging results in terms of activity and efficacy. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1196-1Authors Fotios Loupakis, University of Pisa Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori and Department of Oncology, Transplants and New Technologies in Medicine Via Roma, 67 56126 Pisa ItalyGianluca Masi, University of Pisa Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori and Department of Oncology, Transplants and New Technologies in Medicine Via Roma, 67 56126 Pisa ItalyLorenzo Fornaro, University of Pisa Unit of Medical Oncology 2, Azienda Osp...

top  

  Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy

Conclusions  Our findings indicate that TC was associated with higher rates of FN than reported in the clinical trial. The 25% incidence fulfills the requirement of primary prophylaxis with G-CSF. Routine administration of G-CSF is highly recommended to reduce the rates of FN in breast cancer patients receiving TC. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00520-010-0843-8Authors Alexandre Chan, National University of Singapore Department of Pharmacy, Faculty of Science Block S4, 18 Science Drive 4 Singapore Singapore 117543Wing Hang Fu, National University of Singapore Department of Pharmacy, Faculty of Science Block S4, 18 Science Drive 4 Singapore Singapore 117543Vivianne Shih, National Cancer Centre Singapore Department of Pharmacy Singapo...

top  

  Mylan S.A.S. Withdraws Its Marketing Authorisation Application For Docetaxel Mylan (docetaxel), Europe

The European Medicines Agency has been formally notified by Mylan S.A.S. of its decision to withdraw its application for a centralised marketing authorisation for the medicinal product Docetaxel Mylan (docetaxel), 10mg/ml powder and solvent for solution for infusion. The medicine was developed as a generic medicine to be used for breast cancer, non small cell lung cancer, prostate cancer, gastric adenocarcinoma and head and neck cancer. The reference medicinal product for Docetaxel Mylan is Taxotere, which has been authorised in the European Union since 1995... (Source: Health News from Medical News Today)

top  

  Mylan S.A.S. Withdraws Its Marketing Authorisation Application For Docetaxel Mylan (docetaxel), Europe

The European Medicines Agency has been formally notified by Mylan S.A.S. of its decision to withdraw its application for a centralised marketing authorisation for the medicinal product Docetaxel Mylan (docetaxel), 10mg/ml powder and solvent for solution for infusion... (Source: Cancer / Oncology News From Medical News Today)

top  

  Investigational drug may boost survival for certain prostate cancer patients

Cabazitaxel, an investigational compound under development by Sanofi-aventis, plus prednisone/prednisolone, is associated with overall survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease advanced after treatment with docetaxel-based chemotherapy. (Source: Modern Medicine)

top  

  Investigational drug may boost survival for certain prostate cancer patients

Cabazitaxel, an investigational compound under development by Sanofi-aventis, plus prednisone/prednisolone, is associated with overall survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease advanced after treatment with docetaxel-based chemotherapy. (Source: Drug Topics - Pharmacy News)

top  

  Investigational drug may boost survival for certain prostate cancer patients

Cabazitaxel, an investigational compound under development by Sanofi-aventis, plus prednisone/prednisolone, is associated with overall survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease advanced after treatment with docetaxel-based chemotherapy. (Source: Drug Topics - Clinical News)

top  

  Investigational drug may boost survival for certain prostate cancer patients

Cabazitaxel, an investigational compound under development by Sanofi-aventis, plus prednisone/prednisolone, is associated with overall survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease advanced after treatment with docetaxel-based chemotherapy. (Source: Drug Topics - Top News)

top  

  Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer

Conclusion  These data suggest that weekly docetaxel plus carboplatin may be an important therapeutic second-line treatment option for patients with DRPC. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00345-010-0527-5Authors Christoph W. M. Reuter, Hannover Medical School Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation Carl-Neuberg-Str. 1 30625 Hannover GermanyMichael A. Morgan, Hannover Medical School Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation Carl-Neuberg-Str. 1 30625 Hannover GermanyPhilipp Ivanyi, Hannover Medical School Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation Carl-Neuberg-Str. 1 30625 Hannover GermanyMartin Fenner, Hannover Medical School Dep...

top  

  Genentech Provides Update On Phase III Study Of Avastin In Men With Late Stage Prostate Cancer

Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute (NCI) investigating the use of Avastin® (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC). The study, known as CALGB 90401, did not meet its primary objective of extending overall survival compared to chemotherapy and prednisone alone... (Source: Health News from Medical News Today)

top  

  Two Phase 3 Trials Of Sunitinib With Commonly Used Chemotherapies In Advanced Breast Cancer Did Not Meet The Primary Endpoint

Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone... (Source: Health News from Medical News Today)

top  

  Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma

Conclusion  In all, the DocMitoCape regimen exhibited a favorable safety profile and a high rate of tumor stabilizations in patients with pre-treated gallbladder, bile duct and pancreatic carcinoma. It might be considered after failure of standard regimens in these types of cancer. Content Type Journal ArticleCategory Original PaperDOI 10.1007/s00432-010-0843-6Authors Jens Kruth, Universitätsmedizin Mannheim, Ruprecht-Karls-Universität Heidelberg III. Medizinische Klinik, Hämatologie und Onkologie Theodor-Kutzer-Ufer 1-3 68167 Mannheim GermanyJohanna Nissen, Universitätsmedizin Mannheim, Universität Heidelberg Institut für Klinische Radiologie und Nuklearmedizin Theodor-Kutzer-Ufer 1-3 68167 Mannheim GermanyThomas Ernst, Universitätsmedizin Mannheim, Ruprecht-...

top  

  Roche provides update on phase III study of Avastin in men with late stage prostate cancer

Roche announced today the topline results of a phase III trial led by the US Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC). The study, known as CALGB 90401, did not meet its primary objective of extending overall survival compared to chemotherapy and prednisone alone. A preliminary assessment of safety performed by CALGB has shown adverse events that have been previously observed in pivotal trials with Avastin. (Source: Roche Media News)

top  

  Roche provides update on phase III study of Avastin in men with late stage prostate cancer

Roche announced today the topline results of a phase III trial led by the US Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC). The study, known as CALGB 90401, did not meet its primary objective of extending overall survival compared to chemotherapy and prednisone alone. A preliminary assessment of safety performed by CALGB has shown adverse events that have been previously observed in pivotal trials with Avastin. Data from the study will be submitted by CALGB for presentation at the 2010 American Society of Clinical Oncology (ASCO) annual meeting, June 4 to 8, 2010. (Source: Roche Inves...

top  

  Sunitinib fails to achieve primary endpoint measures in breast cancer trials

Source: PharmaTimes Area: News PharmaTimes reports that sunitinib has failed to achieve the primary endpoint measure in 2 phase III studies testing the drug in advanced breast cancer. The SUN 1064 study investigated use of sunitinib with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer but did not show a significant improvement in progression-free survival (PFS) compared to the chemotherapy alone. In the SUN 1099 trial, sunitinib in combination with capecitabine failed to show significant improvements in PFS compared with capecitabine alone in previously-treated advanced breast cancer patients. No further study data are available in the PharmaTimes story.   The story also reports that Pfizer (the manufacturer of sunitinib) has also ann...

top  

  Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer

In conclusion, weekly DTX-based chemotherapy was no less effective and less toxic than triweekly DTX-based chemotherapy for HRPC patients and therefore can be useful as the first-line chemotherapy regimen for HRPC patients, especially the elderly or those with a poor performance status. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10156-010-0047-7Authors Tomihiko Yasufuku, Kobe University Graduate School of Medicine Division of Urology, Department of Surgery 7-5-1 Kusunoki-cho, Chuo-ku Kobe 650-0017 JapanKatsumi Shigemura, Kobe University Graduate School of Medicine Division of Urology, Department of Surgery 7-5-1 Kusunoki-cho, Chuo-ku Kobe 650-0017 JapanOsamu Matsumoto, Miki City Hospital Department of Urology Miki JapanSoichi Arakawa, Kobe University Gradua...

top  

  Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer

Bevacizumab has recently been demonstrated to prolong overall survival when added to carboplatin and paclitaxel for chemotherapy-naïve patients with nonsquamous nonsmall-cell lung cancer (NSCLC). However, the effects of combining bevacizumab with other standard, front-line, platinum-based doublets have not been extensively explored. We designed this single treatment arm, phase 2 trial to determine whether the combination of carboplatin, docetaxel, and bevacizumab is tolerable and prolongs progression-free survival of chemotherapy-naïve patients with advanced, nonsquamous NSCLC.Forty patients were treated with up to 6 cycles of carboplatin (AUC 6), docetaxel (75 mg/m2), and bevacizumab (15 mg/kg) on Day 1 every 21 days. Patients with an objective response or stable disease received mainte...

top  

  Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells

Conclusions  The combination of taxane and SAHA could be efficacious for the treatment of gastric cancer. The genes that were related to the synergistic response to taxane and SAHA could serve as surrogate biomarkers to predict the therapeutic response in gastric cancer patients. Content Type Journal ArticleCategory Original PaperDOI 10.1007/s00432-010-0849-0Authors Hyun Chang, Yonsei University College of Medicine Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center #134, Shinchon-Dong, Seodaemoon-gu Seoul 120-752 KoreaSun Young Rha, Yonsei University College of Medicine Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center #134, Shinchon-Dong, Seodaemoon-gu Seoul 120-752 KoreaHei-Cheul Jeung, Yonsei Unive...

top  

  A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer

Conclusions  Oral panobinostat with and without docetaxel is feasible, and docetaxel had no apparent effect on the pharmacokinetics of panobinostat. Since preclinical studies suggest a dose-dependent effect of panobinostat on PSA expression, and other phase I data demonstrate that intravenous panobinostat produces higher peak concentrations (>20- to 30-fold) and area under the curve (3.5x–5x), a decision was made to focus the development of panobinostat on the intravenous formulation to treat CRPC. Content Type Journal ArticleCategory Clinical Trial ReportDOI 10.1007/s00280-010-1289-xAuthors Dana Rathkopf, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center Genitourinary Oncology Service, Department of Medicine 1275 Yo...

top  

  Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial

Conclusions  A sequential strategy with TCF-dd followed by COFFI is very active and may be of special interest in selected patients. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1281-5Authors Matteo Dalla Chiesa, Azienda Ospedaliera di Cremona Departments of Medical Oncology and Biostatistics Cremona ItalyGianluca Tomasello, Azienda Ospedaliera di Cremona Departments of Medical Oncology and Biostatistics Cremona ItalySebastiano Buti, Azienda Ospedaliera di Cremona Departments of Medical Oncology and Biostatistics Cremona ItalyRodrigo Kraft Rovere, Azienda Ospedaliera di Cremona Departments of Medical Oncology and Biostatistics Cremona ItalyMatteo Brighenti, Azienda Ospedaliera di Cremona Departments of Medical Oncology and Biostatistics Cre...

top  

  Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study

To investigate the potential benefit of reintroducing docetaxel chemotherapy in patients with progressive metastatic castration-resistant prostate cancer (mCRPC) who had initially responded to first-line docetaxel-based regimen. Records were evaluated retrospectively from French patients with mCRPC who had been included in seven controlled clinical studies of docetaxel as first-line treatment. We identified patients who were confirmed as responders to first-line treatment, discontinued for reasons other than disease progression or unacceptable toxicity, and who received further docetaxel chemotherapy for disease progression. The primary objective was to assess efficacy in terms of the prostate-specific antigen (PSA) response after resuming a docetaxel-based chemotherapy. Secondary objectiv...

top  

  Comment on Pegylated Liposomal Doxorubicin Plus Docetaxel in Metastatic Breast Cancer [CORRESPONDENCE]

(Source: Journal of Clinical Oncology)

top  

  Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins

Conclusions: High performing DDR focus formation resulted in tumor resistance to DNA damage-inducing chemotherapy. Our results suggested an importance of evaluation of DDR competence to predict breast cancer chemosensitivity, and merits further studying into its usefulness in exclusion of non-responder patients. (Source: Breast Cancer Research)

top  

  Horizon Scanning: Cabazitaxel found to improve survival in prostate cancer patients in Phase III study

Source: PharmaTimes Area: News According to PharmaTimes, Phase III data relating to cabazitaxel have been presented by the company developing it (Sanofi-Aventis). The drug is under development for prostate cancer and the study found cabazitaxel improved overall and progression-free survival in patients with metastatic hormone-refractory prostate cancer whose disease progressed following chemotherapy with docetaxel.   The study, (called TROPIC study), involved 755 men with advanced prostate cancer who received either a combination of cabazitaxel and prednisone or mitoxantrone and prednisone. The results found an overall median survival of 15.1 months in the cabazitaxel arm compared to 12.7 months in the mitoxantrone arm. Patients in the cabazitaxel arm also experienced an increase...

top  

  A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NF[kappa]B and generating reactive oxygen species

To characterize the molecular changes associated with DMAPT-induced prostate cancer cell death and its in vivo activity.CWR22Rv1 and PC-3 were subjected to flow cytometry, electrophoretic mobility shift assays, and Western blot studies to measure DMAPT's ability to generate reactive oxygen species (ROS), inhibit NF[kappa]B DNA binding, and cause changes in anti-apoptotic proteins. N-acetyl cysteine (NAC) and short hairpin RNA (shRNA) were used to determine the contribution of ROS and JNK2 activation, respectively. The BrdU incorporation assay was used to measure proliferation and trypan blue studies assessed cell viability after DMAPT treatment. The in vivo activity of DMAPT as a single agent and in combination with bicalutamide or docetaxel was assessed in a subcutaneous xenograft model w...

top  

  Cabazitaxel Increased Survival for Patients with Advanced Hormone-Refractory Prostate Cancer

- Results observed in patients treated with cabazitaxel plus prednisone whose disease progressed despite prior docetaxel-based chemotherapy - - Data from large international Phase 3 study to be presented at the 2010 Genitourinary Cancers Symposium... (Source: Drugs.com - Clinical Trials)

top  

  Cabazitaxel Increased Survival For Patients With Advanced Hormone-Refractory Prostate Cancer

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced results from a Phase 3 trial which demonstrated cabazitaxel, an investigational compound, plus prednisone/prednisolone significantly improved overall survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease progressed following treatment with docetaxel-based chemotherapy. The TROPIC trial compared the combination of cabazitaxel plus prednisone/prednisolone to the active agent mitoxantrone plus prednisone/prednisolone... (Source: Health News from Medical News Today)

top  

  Cabazitaxel Increased Survival For Patients With Advanced Hormone-Refractory Prostate Cancer

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced results from a Phase 3 trial which demonstrated cabazitaxel, an investigational compound, plus prednisone/prednisolone significantly improved overall survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease progressed following treatment with docetaxel-based chemotherapy... (Source: Pharma Industry News From Medical News Today)

top  

  Peripheral olfactory sensitivity in rodents after treatment with docetaxel

Clinical studies have documented that cytotoxic chemotherapy is often associated with body weight loss and decreased enjoyment of food. Besides taste, olfaction plays a role in food intake. We assessed whether systemic chemotherapeutic cancer treatment compromises olfactory function in rats and mice treated with docetaxel (Taxotere; Sanofi-Aventis, Paris, France).Randomized, controlled trials on mice and rats.Male mice received a single and male rats either a single, two, or three docetaxel administrations. Olfactory function was tested by means of electroolfactograms (EOGs) from the chemosensory epithelium of the nasal septum and the endoturbinates. We evaluated and compared the magnitude of EOG responses evoked by different odorants recorded at different time points after treatment.In bo...

top  

  ASCO: Drug Prolongs Survival in Metastatic Prostate Cancer

While the investigational drug cabazitaxel prolongs survival in men with metastatic prostate cancer progressing after treatment with a docetaxel-containing regimen, hormone therapy plus radiation improves survival and reduces recurrence in men with intermediate-risk early-stage prostate cancer, according to two studies presented at the 2010 Genitourinary Cancers Symposium, held from March 5 to 7 in San Francisco. (Source: Modern Medicine)

top  

  Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer

Conclusion  S-1 exhibits modest activity and acceptable toxicity when used as a third or subsequent line of chemotherapy in patients with advanced NSCLC. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10147-010-0034-0Authors Akira Ono, Shizuoka Cancer Center Division of Thoracic Oncology 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun Shizuoka 411-8777 JapanTateaki Naito, Shizuoka Cancer Center Division of Thoracic Oncology 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun Shizuoka 411-8777 JapanHaruyasu Murakami, Shizuoka Cancer Center Division of Thoracic Oncology 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun Shizuoka 411-8777 JapanToshiaki Takahashi, Shizuoka Cancer Center Division of Thoracic Oncology 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun Shizuoka...

top  

  Recurrent Male Breast Cancer Accompanied by Carcinomatous Pleuritis That Responded to Combination Therapy with High-Dose Toremifene and Docetaxel

Breast Care 2010;5:29-32 (DOI:10.1159/000265156) (Source: Breast Care : Last 20 articles)

top  

  Patient-Derived First Generation Xenografts of Non-Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy.

CONCLUSIONS: Models based on first generation NSCLC subrenal capsule xenografts have been developed, which are suitable for quick assessment (6-8 weeks) of the chemosensitivity of patients' cancers and selection of the most effective regimens. They hold promise for application in personalized chemotherapy of NSCLC patients. Clin Cancer Res; 16(5); 1442-51. PMID: 20179238 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)

top  

  A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer.

Authors: Venturini M, Bighin C, Puglisi F, Olmeo N, Aitini E, Colucci G, Garrone O, Paccagnella A, Marini G, Crinò L, Mansutti M, Baconnet B, Barbato A, Del Mastro L To evaluate the cardiotoxicity, general toxicity, and activity of non-pegylated liposomal doxorubicin, in combination with docetaxel and trastuzumab, as first-line therapy in metastatic breast cancer. Thirty-one patients with metastatic human epidermal growth factor receptor 2-overexpressing breast cancer, who had not previously received chemotherapy for metastatic disease, received non-pegylated liposomal doxorubicin (50mg/m(2)), docetaxel (75mg/m(2)) and trastuzumab (2mg/kg/week) for up to eight cycles, followed by trastuzumab alone for up to 52 weeks. Cardiotoxicity was defined as a decrease in left ventricular eje...

top  

  Aflibercept/cisplatin/docetaxel/fluorouracil: Delayed wound healing (first report with aflibercept): case report

(Source: Reactions)

top  

  N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial

Conclusions: Weekly dosing of combination of irinotecan and docetaxel is active against MBC. However, the response rate to our regimen was not significantly better than single-agent docetaxel. Other schedules of irinotecan plus docetaxel should be considered for future studies. (Source: Annals of Oncology)

top  

  Primary Metastatic Leiomyosarcoma of the Fallopian Tube: A Rare Case Report.

Conclusions: Primary metastatic leiomy-osarcoma of the fallopian tube is a progressive disease with limited therapy options. For better prognostic evaluation and disease management in such rare cases, it is important to report and compare more cases regarding course of disease and outcome. PMID: 20164662 [PubMed - as supplied by publisher] (Source: Onkologie)

top  

  European CHMP issues positive opinion on marketing authorisation application for Docefrez® (generic docetaxel)

Source: EMEA Area: News The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion, recommending the granting of a marketing authorisation for Docefrez (generic docetaxel), for the treatment of breast cancer, NSCLC, prostate cancer, gastric adenocarcinoma, and head and neck cancer. (Source: NeLM - News)

top  

  Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099 [Thoracic Oncology]

Conclusion The addition of cetuximab to TC did not significantly improve the primary end point, PFS-IRRC. There was significant improvement in ORR by IRRC. The difference in OS favored cetuximab but did not reach statistical significance. (Source: Journal of Clinical Oncology)

top  

  Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer [Breast Cancer]

Conclusion HTX is an effective and feasible first-line therapy for HER2-positive locally advanced or metastatic breast cancer, although it should be reserved for patients with good performance status who are not receiving long-term steroids. (Source: Journal of Clinical Oncology)

top  

  Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer.

CONCLUSION: Surgery following docetaxel-based chemotherapy was safe and with similar morbidity to immediate surgery in patients with locally-advanced resectable gastric carcinoma. PMID: 20143466 [PubMed - in process] (Source: World Journal of Gastroenterology : WJG)

top  

  The combination of docetaxel and cisplatin plus fluorouracil as neoadjuvant chemotherapy in the treatment of T4 stage gastric cancer

Abstract: The prognosis of local advanced gastric carcinoma is very poor. We evaluated the impact on survival and the effects induced by the triple combination docetaxel–cisplatin–fluorouracil (DCF) as neoadjuvant chemotherapy in 24 T4 stage gastric tumor patients. They received 2–3 cycles DCF chemotherapy, followed by radical gastric resection. Tumor downstaging detected by CT was obtained in 17 out of 24 patients. The overall 3-year survival rate was 68.2%. Patients who received R0 resection (19/22) showed a 3-year survival rate of 78.9%. T downstaged patients (17/22) showed a higher 3-year survival rate of 82.4%. Those who responded to the triple combination of docetaxel–cisplatin–fluorouracil, exhibited T downstaging and subsequently received an R0 resection had a definitely ...

top  

  Genta Initiates Phase 2 Study Of Tesetaxel, The Leading Clinical-Stage Oral Taxane, In Patients With Advanced Melanoma

Genta Incorporated (OTCBB: GETA) announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma. Tesetaxel is the Company's newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development. The new trial builds on more than ten years of Genta's experience in melanoma clinical research. Unlike standard taxanes (paclitaxel [Taxol®] or docetaxel [Taxotere®]) that must be infused intravenously, tesetaxel is a capsule that can be taken by mouth... (Source: Health News from Medical News Today)

top  

  A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer

Conclusions Intetumumab was generally safe and well tolerated in combination with docetaxel, with a higher incidence of TEAEs in the 10 mg/kg dose cohort. The efficacy of 10 mg/kg intetumumab in combination with docetaxel appears to warrant further study. Content Type Journal ArticleCategory PHASE I STUDIESDOI 10.1007/s10637-010-9388-4Authors Franklin M. Chu, San Bernardino Urological Associates Medical Group San Bernardino CA USAJoel Picus, Washington University School of Medicine Alvin J. Siteman Cancer Center St. Louis MO USAPaula M. Fracasso, Washington University School of Medicine Alvin J. Siteman Cancer Center St. Louis MO USARobert Dreicer, Cleveland Clinic Cleveland OH USAZhihui Lang, Centocor Research and Development, Inc Malvern PA USABrenda Foster, Centocor Rese...

top  

  FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer.

CONCLUSION: We provide the evidence that FGFR4 388Arg is an independent predictor of pCR following AC-Doc as NCT in PBC. PMID: 20147743 [PubMed - as supplied by publisher] (Source: Ann Oncol)

top  

  New Drug May Offer More Hope for Men With Advanced Prostate Cancer

Abiraterone, an experimental drug that is entering the later stages of clinical testing, has shown good results in men with advanced prostate cancer who have already been treated with both hormones and chemotherapy (specifically the chemotherapy agent docetaxel). Abiraterone had previously shown promising results when given to men who had never underwent chemotherapy. The new testing showed that men with advanced prostate cancer had significantly lower PSA levels and fewer circulating tumor cells when given abiraterone. The results of this most recent study can be found in the Journal of Clinical Oncology. New Drug May Offer More Hope for Men With Advanced Prostate Cancer originally appeared on About.com Prostate Cancer on Wednesday, February 17th, 2010 at 23:01:46.Permalink | Comment | Em...

top  

  A New Therapy Paradigm for Prostate Cancer Founded on Clinical Observations.

Authors: Efstathiou E, Logothetis CJ Efficacy equivalent to that reported in other common adult solid tumors considered to be chemotherapy-sensitive has been reported with Docetaxel in patients with castrate-resistant prostate cancer. However, in contrast to other cancers, the expected increase in efficacy with the use of chemotherapy in earlier disease states has not been reported to date in prostate cancer. On the basis of these observations, we speculated that the therapy development paradigm used successfully in other cancers may not apply to the majority of prostate cancers. Several lines of supporting clinical and experimental observations implicate the tumor microenvironment in prostate carcinogenesis and resistance to therapy. We conclude that a foundation to guide the developm...

top  

  Randomized Phase III Trial of Gefitinib versus Docetaxel in Non-Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy.

CONCLUSIONS: The primary endpoint of progression-free survival was longer with gefitinib than docetaxel, and the secondary endpoints showed superior objective response rate, good tolerability, and similar quality of life improvement rates for gefitinib than docetaxel. Therefore, gefitinib is an important valid treatment option for second-line therapy for Korean NSCLC patients. Clin Cancer Res; 16(4);1307-14. PMID: 20145166 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)

top  

  Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer.

Authors: Zoubeidi A, Chi K, Gleave M Many strategies used to kill cancer cells induce stress-responses that activate survival pathways to promote emergence of a treatment resistant phenotype. Secretory clusterin (sCLU) is a stress-activated cytoprotective chaperone up-regulated by many varied anticancer therapies to confer treatment resistance when overexpressed. sCLU levels are increased in several treatment recurrent cancers including castrate resistant prostate cancer, and therefore sCLU has become an attractive target in cancer therapy. sCLU is not druggable with small molecule inhibitors, therefore nucleotide-based strategies to inhibit sCLU at the RNA level are appealing. Preclinical studies have shown that antisense oligonucleotide (ASO) or siRNA knockdown of sCLU have preclinic...

top  

  Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non-Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial [Thoracic Oncology]

Conclusion These biomarkers do not appear to be predictive factors for differential survival between gefitinib and docetaxel in this setting of previously treated patients; however, subsequent treatments may have influenced the survival results. For secondary end points of PFS and ORR, some advantages for gefitinib over docetaxel were seen in EGFR mutation–positive and high EGFR copy number patients. There was no statistically significant difference between gefitinib and docetaxel in biomarker-negative patients. This suggests gefitinib can provide similar overall survival to docetaxel in patients across a broad range of clinical subgroups and that EGFR biomarkers such as mutation status may additionally identify which patients are likely to gain greatest PFS and ORR benefit from gefi...

top  

  A Phase II Study of Pemetrexed as Second-line Chemotherapy for the Treatment of Metastatic Castrate-resistant Prostate Cancer (CRPC); Hoosier Oncology Group GU03-67

Investigators examined the safety and efficacy of pemetrexed in patients with post-docetaxel castrate-resistant prostate cancer. Annals of Oncology (Source: Medscape Today Headlines)

top  

  Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction

The use of platinum-based chemoradiation for esophageal cancer is routine, but it is unclear which class of cytotoxic are optimum. It was hypothesized that chemoradiotherapy with fluoropyrimidine, taxane, and camptothecin would have preserved or improved efficacy with no compromise in safety.Patients with histologically confirmed, resectable esophageal carcinoma were eligible. In addition to other tests, a baseline endoscopic ultrasonography (EUS) was obtained. Patients were medically fit and had near-normal organ functions. Patients received docetaxel and irinotecan, plus 5-fluorouracil as induction therapy and then the same cytotoxics with 50.4 grays of radiotherapy followed by an attempted surgery. Pathologic complete response (pathCR) at a rate of [ge]20% was the primary endpoint. The ...

top  

  Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer

A study was conducted to determine the 5-year recurrence-free survival in patients with high-risk prostate cancer after neoadjuvant combination chemotherapy followed by surgery. Secondary endpoints included safety, pathologic effects of chemotherapy, and predictors of disease recurrence.Fifty-seven patients were enrolled in a phase 1/2 study of weekly docetaxel 35 mg/m2 and escalating mitoxantrone to 4 mg/m2 before prostatectomy. Patients were treated with 16 weeks of chemotherapy administered weekly on a 3 of every 4 week schedule. A tissue microarray, constructed from the prostatectomy specimens, served to facilitate the exploratory evaluation of biomarkers. The primary endpoint was recurrence-free survival. Disease recurrence was defined as a confirmed serum prostate-specific antigen (P...

top  

  Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer

Conclusion: In non-operable NSCLC patients not eligible for a platinum-based treatment, single-agent docetaxel can provide complete pathologic responses. Failure to obtain a response after the first few cycles should not automatically discourage to continue treatment. (Source: World Journal of Surgical Oncology)

top  

  PSK enhances the efficacy of docetaxel in human gastric cancer cells through inhibition of nuclear factor-kappaB activation and survivin expression.

Authors: Kinoshita J, Fushida S, Harada S, Makino I, Nakamura K, Oyama K, Fujita H, Ninomiya I, Fujimura T, Kayahara M, Ohta T Docetaxel, a member of the taxane family, induces antitumor effects in patients with advanced gastric cancer. However, toxicity at therapeutic doses can be severe, resulting in discontinuation of therapy. It is possible that dose reduction due to adverse events may decrease the cytotoxic efficacy of docetaxel. PSK, a protein-bound polysaccharide, has been used as a chemoimmunotherapy agent in the treatment of cancer in Asia for over 30 years. In the present study, we investigated the enhancing effects of PSK on the cytotoxicity of docetaxel in human gastric cancer through non-immunological actions both in vitro and in vivo. The sensitization effects of PSK on d...

top  

  Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: A pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials.

Authors: Jatoi A, Foster NR, Egner JR, Burch PA, Stella PJ, Rubin J, Dakhil SR, Sargent DJ, Murphy BR, Alberts SR Whether elderly patients with metastatic esophageal, gastroesophageal, and gastric cancer do as well with chemotherapy as their younger counterparts was investigated in this pooled analysis. In total, 367 patients from 8 consecutive, first-line trials were included: i) etoposide + cisplatin; ii) 5-fluorourucil + leucovorin; iii) 5-fluorouracil + levamisole; iv) irinotecan; v) docetaxel + irinotecan; vi) oxaliplatin + capecitabine; vii) docetaxel + capecitabine; and viii) bortezomib + paclitaxel + carboplatin. One hundred and fifty-four (42%) patients were >/=65 years old (range: 65-86), and 213 younger (range: 20-64). Elderly patients had worse performance scores (2-3): ...

top  

  A population-based gene signature is predictive of breast cancer survival and chemoresponse.

This study sought to develop a prognostic scheme based on a 28-gene signature in a broad patient population, including those with advanced disease. Clinically annotated transcriptional profiles of 1,734 breast cancer patients were obtained to validate the 28-gene signature in prognostic categorization. The 28-gene signature generated significant patient stratification with regard to breast cancer disease-free survival (log-rank P<0.0001; n=1,337) and overall survival (log-rank P<0.0001; n=806) in Kaplan-Meier analyses. The gene expression signature provides refined prognosis of disease-free survival (log-rank P<0.006; Kaplan-Meier analysis) within each classic clinicopathologic factor-defined subgroup, including LN-, LN+, ER-, ER+ and tumor grade II. Furthermore, it was investigat...

top  

  A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer

Abstract  The optimal adjuvant treatment for gastric cancer remains controversial. We compared the efficacy of a docetaxel and platinum adjuvant chemotherapy regimen, in patients with high-risk gastric cancer, with that of the same chemotherapy plus radiation therapy (RT). In addition, we evaluated the prognostic and/or predictive value of a panel of molecular markers. Patients with histologically proven, radically resected gastric cancer, stage ≥T3 and/or N+ were randomized to 6 cycles of docetaxel with cisplatin, both at 75 mg/m2 every 3 weeks (arm A) or the same treatment with RT (arm B; 45 Gy). Due to excessive nausea and vomiting, cisplatin was substituted by carboplatin at AUC (area under the curve) of 5 after the first 45 patients (22 group ...

top  

  Carboplatin with weekly docetaxel and ifosfamide in advanced head and neck cancers: a phase I Brown University Oncology Group dose escalation study (HN-93)

Conclusions  This novel regimen of carboplatin with weekly docetaxel and ifosfamide has a favorable toxicity profile and is active in this setting. Phase II study results are awaited. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1251-yAuthors Ritesh Rathore, Roger Williams Hospital Division of Hematology/Oncology 825 Chalkstone Avenue Providence RI 02908 USAAriel Birnbaum, Rhode Island Hospital Division of Hematology/Oncology Providence RI USABharti Rathore, Roger Williams Hospital Division of Hematology/Oncology 825 Chalkstone Avenue Providence RI 02908 USAThomas DiPetrillo, Rhode Island Hospital Department of Radiation Oncology Providence RI USATeresa Kennedy, Brown University Oncology Group Providence RI USANeal Ready, Duke Medical Cent...

top  

  Transverse leukonychia (Mees' lines) associated with docetaxel

(Source: The Journal of Dermatology)

top  

  Phase II Evaluation of Liposomal Doxorubicin with Docetaxel in Patients with Metastatic Breast Cancer

Breast Care 2010;5:1 (DOI:10.1159/000272119) (Source: Breast Care : Last 20 articles)

top  

  Chemotherapy: Satraplatin delays progression in prostate cancer

Nature Reviews Clinical Oncology 7, 69 (2010). doi:10.1038/nrclinonc.2009.230 Author: Lisa Hutchinson Prostate cancer is the second most common cancer in men worldwide. The FDA approved docetaxel in 2004 as first-line treatment for men with castrate-refractory prostate cancer (CRPC) and this is now the standard treatment for such patients. Patients with metastatic disease, however, eventually discontinue docetaxel (Source: Nature Clinical Practice Oncology)

top  

  [Articles] Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Patients with non-small-cell lung cancer harbouring mutations in the epidermal growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase inhibitor gefitinib. However, whether gefitinib is better than standard platinum doublet chemotherapy in patients selected by EGFR mutation is uncertain. (Source: The Lancet Oncology)

top  

  Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison

Background: Combinations of trastuzumab with either docetaxel or vinorelbine are considered valuable treatment options for HER2-positive metastatic breast cancer patients. We performed a retrospective comparison of the clinical outcomes associated with either one of these combinations. Methods: From a multi-institutional database we retrieved 179 patients treated with either docetaxel or vinorelbine plus trastuzumab as first-line therapy for HER2-positive advanced breast cancer. Results: Docetaxel-trastuzumab was superior to vinorelbine-trastuzumab in terms of response rate (RR: 77 vs 57%, p=0.01) and median overall survival (OS: 35 vs 23 months, p=0.04), but not in median time to progression (TTP: 12 vs 10 months, p=0.53). At multivariate analysis, type of treatment was not associated wit...

top  

  Fibronectin confers survival against chemotherapeutic agents but not against radiotherapy in DU145 prostate cancer cells: Involvement of the insulin like growth factor-1 receptor

Tumor growth is influenced by an increase in cell proliferation and a reduction in apoptosis; both of which are affected by alterations in extracellular matrix (ECM). Our aim was to assess if the susceptibility of prostate cancer cells to apoptosis induced by either chemotherapeutics or radiotherapy was altered by changes in the ECM.Prostate cancer cell lines LNCaP and DU145 (androgen independent) cells were treated with chemotherapeutics (ceramide and docetaxel) or radiotherapy in the presence or absence of fibronectin, laminin, or vitronectin. Cell death was assessed using Trypan blue cell counting and apoptosis was confirmed by measuring PARP cleavage by Western immunoblotting (WIB). To identify a mechanism of action, changes in the abundance (WIB) or association (immunoprecipitation fo...

top  

  Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents.

Authors: Yardley DA Patients with metastatic breast cancer (MBC) have poor prognoses and 5-year survival rates of approximately 20%. The site(s) and degree of metastatic dissemination are among the principal prognostic factors for patients with MBC. Patients with visceral metastases to the liver and/or lung have a very poor prognosis. Although good performance status, restricted disease dissemination, and limited extent of metastatic infiltration are associated with higher responses to chemotherapy, responses are generally short lived, with rapid disease progression after treatment failure. Thus, novel strategies for the management of patients with MBC with visceral disease are urgently needed. We have analyzed outcomes of trials that evaluated various chemotherapeutic agents as monoth...

top  

  Rapamycin enhances the susceptibility of both androgen-dependent and -independent prostate carcinoma cells to docetaxel.

CONCLUSIONS: RPM could significantly increase the susceptibility of both androgen-dependent and -independent PC cells to DOC; the synergy of RPM and DOC was demonstrated. RPM enhanced the DOC-induced upregulation of caspase activity, resulting in an increasing number of cells in sub-G1 phases. The synergy of the combined treatment might be observed in both androgen-dependent and -independent PC cell lines. PMID: 20193259 [PubMed - in process] (Source: Chinese Medical Journal)

top  

  Triplet Chemotherapy with Cisplatin, Docetaxel, and Irinotecan for Patients with Recurrent or Refractory Non-small Cell Lung Cancer.

The objective response rate was 39.1% (95% confidence interval:18.7-59.5%). The median survival time and actual 2-, 3-, and 5-year survival rates were 14.3 months, 32%, 20%, and 8%, respectively. Of note, only 6 patients were treated with gefitinib at the recurrence after triplet chemotherapy;of these, 4 (67%) achieved a partial response, which might result in favorable survival. Grade 3/4 toxicities consisted of neutropenia (100%), neutropenic fever (56%), nausea/vomiting (40%), and diarrhea (16%);no cases of treatment-related death occurred. Triplet chemotherapy showed impressive survival data in our clinical trial, but proved too toxic for use in treating patients with NSCLC in the clinical practice. PMID: 20200582 [PubMed - as supplied by publisher] (Source: Acta Med Okayama)

top  

  Overcoming Taxane Resistance in Cancer

Proteomics study reveals a protein that, when suppressed, makes cancers more susceptible to chemotherapy BOSTON, Jan. 25 /PRNewswire-USNewswire/ -- Taxanes, a group of cancer drugs that includes paclitaxel (Taxol®) and docetaxel (Taxotere®),... (Source: Drugs.com - Clinical Trials)

top  

  A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer

Conclusions: The combination of ABT-751 and docetaxel is safe and active in CRPC. Based on the cumulative safety analysis, the recommended phase II dose of ABT-751 is 200 mg daily with docetaxel 60 mg/m2 for this patient population. (Source: Annals of Oncology)

top  

  Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials

Conclusions: TEC chemotherapy has significant clinical activity in CRPC. A randomized, controlled trial evaluating the addition of carboplatin to taxane-based chemotherapy is needed to elucidate the value of carboplatin in CRPC. (Source: Annals of Oncology)

top  

  Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy

Conclusion: Sunitinib malate demonstrated promising activity in metastatic CRPC progressing after prior docetaxel. (Source: Annals of Oncology)

top  

  A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis

Conclusions: The incidence of dacryostenosis in patients receiving weekly docetaxel was not different for the AT- and the CS-treated eyes. The dacryostenosis was predominantly mild, not leading to surgical interventions. (Source: Annals of Oncology)

top  

  North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer

Conclusion: TX-BV demonstrated significant activity; dose modifications were required to manage drug-related toxic effects. (Source: Annals of Oncology)

top  

  Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population

Conclusions: Pemetrexed as a second-line treatment option for patients with a predominantly nonsquamous histology in NSCLC is a cost-effective alternative to docetaxel according to the 30000 euros/QALY threshold commonly accepted in Spain. (Source: BMC Cancer)

top  

  Proteomics Study Reveals A Protein That, When Suppressed, Makes Cancers More Susceptible To Chemotherapy

Taxanes, a group of cancer drugs that includes paclitaxel (Taxol®) and docetaxel (Taxotere®), have become front-line therapy for a variety of metastatic cancers. But as with many chemotherapy agents, resistance can develop, a frequent problem in breast, ovarian, prostate and other cancers. Now, cancer researchers at Children's Hospital Boston report a protein previously unknown to be involved in taxane resistance and that could potentially be targeted with drugs, making a cancer more susceptible to chemotherapy... (Source: Health News from Medical News Today)

top  

  Proteomics Study Reveals A Protein That, When Suppressed, Makes Cancers More Susceptible To Chemotherapy

Taxanes, a group of cancer drugs that includes paclitaxel (Taxol®) and docetaxel (Taxotere®), have become front-line therapy for a variety of metastatic cancers. But as with many chemotherapy agents, resistance can develop, a frequent problem in breast, ovarian, prostate and other cancers... (Source: Cancer / Oncology News From Medical News Today)

top  

  ResearchPoint & Azaya Therapeutics Announce First Patient Enrolled In Phase I Clinical Study

ResearchPoint and Azaya Therapeutics, Inc. are proud to announce the study initiation and enrollment of the first patient in the phase I clinical study of ATI-1123, a new formulation of docetaxel. ATI-1123 has the same active ingredient as the FDA approved drug Taxotere® (docetaxel). The study is being conducted at two premier Texas cancer centers in patients with advanced solid tumors. The open-label, dose escalation study is being managed by ResearchPoint, a leading Texas-based CRO with extensive oncology trial experience... (Source: Health News from Medical News Today)

top  

  ResearchPoint & Azaya Therapeutics Announce First Patient Enrolled In Phase I Clinical Study

ResearchPoint and Azaya Therapeutics, Inc. are proud to announce the study initiation and enrollment of the first patient in the phase I clinical study of ATI-1123, a new formulation of docetaxel. ATI-1123 has the same active ingredient as the FDA approved drug Taxotere® (docetaxel). The study is being conducted at two premier Texas cancer centers in patients with advanced solid tumors... (Source: Cancer / Oncology News From Medical News Today)

top  

  Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer

Conclusions  Non-cytotoxic suramin, in combination with docetaxel 56 mg/m2 or gemcitabine 1,250 mg/m2, was reasonably well-tolerated with a manageable toxicity profile. Target plasma concentrations were correctly predicted by our previously described dosing nomogram. The observed preliminary evidence of antitumor activity encourages evaluation of this strategy in efficacy trials. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1252-xAuthors Elaine T. Lam, The Ohio State University Department of Internal Medicine, Division of Hematology and Oncology Columbus OH USAJessie L.- S. Au, The Ohio State University College of Pharmacy Columbus OH USAGregory A. Otterson, The Ohio State University Department of Internal Medicine, Division of ...

top  

  Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer

The objective of the current study was to evaluate the efficacy and tolerability of a weekly formulation of DCF.Data from 117 patients treated at The University of Texas M. D. Anderson Cancer Center from 2002 to 2006 with a weekly formulation of DCF were retrospectively collected. A total of 95 patients received front-line therapy with 20 mg/m2 of cisplatin, 350 mg/m2 of 5-fluorouracil, and 20 mg/m2 of docetaxel administered once weekly for 6 consecutive weeks followed by a 2-week break.Ninety-five patients (median age, 62 years [range, 33 to 87 years], with an Eastern Cooperative Oncology Group performance status of 1 or 2 in 67%) received a median of 10 weeks of DCF treatment (range, 3-41 weeks). Grade 3 or 4 hematologic toxicity (assessed according to National Cancer Institute Common To...

top  

  Targeted therapeutic approaches for hormone-refractory prostate cancer

Summary: Prostate cancer is one of the leading causes of cancer related death in men, and remains incurable in the metastatic setting. Despite the initial response to androgen deprivation, the disease gradually progresses to a hormone-refractory state due to cumulative genetic alterations in tumour cells or the microenvironment. Docetaxel represents the first chemotherapeutic agent with a small survival benefit for metastatic hormone-refractory prostate cancer (HRPC). In an attempt to improve survival benefit, several novel drugs targeting specific pathways involved in cell signaling, proliferation, angiogenesis, apoptosis and immune modulation are currently under investigation either as single agents or in combination with cytotoxic drugs. Clinical trials evaluate the inhibition of prosta...

top  

  Azaya signs up first patient in newest docetaxel drug study

Azaya Therapeutics Inc. said Tuesday that the first patient has been enrolled in a pivotal study to gauge the effectiveness of a new formulation of the company’s drug docetaxel. (Source: bizjournals.com Health Care:Biotechnology headlines)

top  

  Cetuximab in combination with taxane and carboplatin does not improve progression-free survival in advance NSCLC

Source: JCO Area: News According to research published early online in the Journal of Clinical Oncology, the addition of cetuximab to the combination of a taxane with carboplatin (TC) does not improve the primary end point, progression-free survival (PFS-IRRC) in NSCLC patients.   Researchers evaluated the efficacy of cetuximab in combination with taxane/carboplatin (TC) vs. TC as first-line treatment of advanced non-small-cell lung cancer (NSCLC) in the BMS099 trial. The phase III study involved 676 chemotherapy-naïve patients with stage IIIB (pleural effusion) or IV NSCLC who were randomised to receive cetuximab in combination with a taxane and carboplatin, or a taxane and carboplatin only. TC consisted of paclitaxel (225 mg/m2) or docetaxel (75 mg/m2), at the investigator's d...

top  

  Effects of Combination of EMAP II with Doxorubicin, Docetaxel, Oxaliplatin and Gemcitabine to Enhance Antitumor Activity in Pancreatic Cancer

Conclusions: In experimental PDAC, there is a differential effect to monotherapy with various cytotoxic agents. Addition of EMAP enhanced docetaxel and gemcitabine effects, but not those after doxorubicin or oxaliplatin. In vitro, EMAP addition increased the antiproliferative effects of doxorubicin, docetaxel and gemcitabine in HUVECs but not in ASPC PDAC cells. This antiendothelial combination therapy may represent an avenue to enhance clinical PDAC therapy with cell-cycle sensitive cytotoxic agents other than gemcitabine. (Source: Journal of Surgical Research)

top  

  Docetaxel, carboplatin and 5-fluorouracil (TCF) chemotherapy in patients with unresectable metastatic carcinoma of cervix.

CONCLUSIONS: The combination of docetaxel, carboplatin and 5-fluorouracil (TCF) appears to have activity in metastatic cervical carcinoma with acceptable toxicity profile. PMID: 20106511 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)

top  

  Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer

Conclusions  Weekly schedule of docetaxel and cisplatin as first-line treatment for NSCLC had good efficacy and manageable toxicity. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1235-yAuthors Jung Hye Kwon, Hallym University Department of Internal Medicine, Kangdong Sacred Heart Hospital, College of Medicine 445 Gil-dong, Gangdong gu Seoul 134-701 South KoreaJung Han Kim, Hallym University Department of Internal Medicine, Kangnam Sacred Heart Hospital, College of Medicine 948-1, Daelim-1dong, Yeongdeugpo-gu Seoul 150-950 South KoreaJung-Ae Lee, Eulji University Hospital Department of Internal Medicine Seo-gu, Dunsan-dong 1306 Daejeon South KoreaHyun Chun Shin, Hallym University Department of Internal Medicine, Chuncheon Sacred Heart Hospita...

top  

  Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial.

CONCLUSION: In this randomised trial, no differences in the efficacy study end points were observed between the two treatment arms. PMID: 20089562 [PubMed - as supplied by publisher] (Source: Ann Oncol)

top  

  Advanced carcinoma of the prostatic urethra in a patient with marked response to chemotherapy, leading to preservation of the bladder

Abstract  We performed transurethral resection of the prostate (TUR-P) for a 66-year-old man with benign prostatic hyperplasia. Pathological examination diagnosed poorly differentiated urothelial carcinoma of the urethra with broad prostatic permeation. Random bladder biopsies showed no malignancy, but a second TUR-P revealed urothelial carcinoma in the prostate and bladder neck. Computed tomography (CT) showed lymph node metastases from para-aortic to right/left external iliac and left obturator nodes, so clinical stage T3N2M0 carcinoma of the prostatic urethra was diagnosed. Given the presence of lymph node metastases, neoadjuvant chemotherapy using cisplatin 70 mg/m2, ifosfamide 1.2 g/m2 and docetaxel 70 mg/m2 (PIT) was considered. After chemotherapy, CT sh...

top  

  Adenocarcinoma of the paranasal sinuses and nasal cavity with lung metastasis showing complete response to combination chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF): A case report

We report the case of a 62-year-old man who presented with nasal congestion and epistaxis. We were unable to observe an oncogenic lesion in the nasal cavity directly, but the tumor gave inhomogeneous low intensity signals on T1-weighted images and an isointense signal on T2-weighted images in MRI. Adenocarcinoma was diagnosed by open biopsy. Six courses of chemotherapy by super-selective intra-arterial infusion of cisplatin with concurrent intensity-modulated radiation therapy of 70Gy were performed at another hospital. However, the tumor enlarged and developed distant metastasis to the lung after this therapy. Therefore, TPF chemotherapy (docetaxel, cisplatin and 5-fluorouracil) was performed 5 times, after which the tumor gradually reduced in size. The patient is alive after a follow-up ...

top  

  Carboplatin/docetaxel: Myelosuppression, nausea and vomiting in an elderly patient: case report

(Source: Reactions)

top  

  Cyclophosphamide/docetaxel/epirubicin: Tumour flare reaction: case report

(Source: Reactions)

top  

  Docetaxel: Stevens-Johnson syndrome and atypical keratinocytes: case report

(Source: Reactions)

top  

  Docetaxel/paclitaxel: Hypersensitivity reaction: 11 case reports

(Source: Reactions)

top  

  The role of docetaxel based therapy for prostate cancer in the era of targeted medicine

Docetaxel based chemotherapy has been shown to modestly extend life, relieve pain and improve the quality of life in patients with metastatic castration-resistant prostate cancer. Current trials are attempting to build on the backbone of docetaxel by combining it with novel biological agents. Trials are also investigating the role of docetaxel for earlier stages of prostate cancer. No standard second-line systemic therapy exists and such patients are candidates for clinical trials. The increased understanding of the mechanisms of progressive castration-resistant prostate cancer is being translated into an increasing pipeline of novel therapies. (Source: International Journal of Urology)

top  

  Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer

This study was performed to evaluate the outcomes of patients with locally advanced breast cancer (LABC) who were treated with a multidisciplinary approach including primary systemic chemotherapy and noncross-resistant adjuvant chemotherapy.Patients with LABC received 4 or 6 cycles of doxorubicin and docetaxel (DT) as primary systemic chemotherapy (PST) every 21 days. Patients with adequate response underwent surgery followed by adjuvant chemotherapy according to pathologic response: complete (pCR), 2 more cycles of DT; partial (pPR), 2 more cycles of DT followed by 6 cycles of cyclophosphamide, methotrexate, and 5-fluorouracil (5-FU) (CMF); and minor (pMR), 6 cycles of CMF. Patients then received radiation and tamoxifen (hormone receptor-positive patients only).Eighty-eight patients were ...

top  

  Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy [Breast Cancer]

Conclusion A low rate of pCR was observed in women with breast cancer and a BRCA1 mutation who were treated with AT or CMF. A high rate of pCR was seen after treatment with cisplatin. An intermediate rate of PCR was associated with AC or FAC. The relative benefits of AC and platinum therapy need to be confirmed through follow-up of this and other cohorts. (Source: Journal of Clinical Oncology)

top  

  Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity

Conclusion: Stable re-expression of CD44s reduces PCa growth and invasion in vitro, and possibly in vivo, suggesting CD44 alterations have potential as gene therapy. When the C-terminus of CD44s is fused to another protein, most phenotypic effects are lessened, particularly hyaluronan adhesion. Finally, CD44v7-10, although it was not functionally significant for growth, may be a target for chemosensitization. (Source: BMC Cancer)

top  

  Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer

Conclusions  The combination of S-1 and docetaxel is well tolerable and has substantial activity for patients with locally advanced or metastatic non-small cell lung cancer. A phase III trial comparing docetaxel with or without S-1 would warrant further investigation. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1239-7Authors Kazuhiro Yanagihara, Kyoto University Hospital Outpatient Oncology Unit Kyoto JapanKenichi Yoshimura, Kyoto University Hospital Department of Clinical Trial Design and Management, Translational Research Center Kyoto JapanMiyuki Niimi, Kyoto University Hospital Department of Clinical Trial Design and Management, Translational Research Center Kyoto JapanHiroyasu Yasuda, Kyoto University Hospital Outpatient Oncology Unit...

top  

  Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

Authors: N C Tebbutt, M M Cummins, T Sourjina, A Strickland, G Van Hazel, V Ganju, D Gibbs, M Stockler, V Gebski & J Zalcberg (Source: British Journal of Cancer AOP)

top  

  Improved Potency and Selectivity of an Oncolytic E1ACR2 and E1B19K Deleted Adenoviral Mutant in Prostate and Pancreatic Cancers.

CONCLUSIONS: These data suggest that the novel oncolytic mutant AdDeltaDelta is a promising candidate for targeting of solid tumors specifically in combination with chemotherapeutics. Clin Cancer Res; 16(2); 541-53. PMID: 20068104 [PubMed - as supplied by publisher] (Source: Cell Research)

top  

  Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer

Authors: A J Armstrong & D J George (Source: Prostate Cancer and Prostatic Diseases)

top  

  Docetaxel: Acute enterocolitis: case report

(Source: Reactions)

top  

  Docetaxel: Fatal acute myeloid leukaemia in an elderly patient: case report

(Source: Reactions)

top  

  Chemosensitization of cancer cells by siRNA using targeted nanogel delivery

Conclusion: This study suggests that targeted delivery of siRNAs by nanogels may be a promising strategy to increase the efficacy of chemotherapy drugs for the treatment of ovarian cancer. In addition, EphA2 is a viable target for therapeutic delivery, and the siRNAs are effectively protected by the nanogel carrier, overcoming the poor stability and uptake that has hindered clinical advancement of therapeutic siRNAs. (Source: BMC Cancer)

top  

  Docetaxel inhibits progression of human hepatoma cell line in vitro and is effective in advanced hepatocellular carcinoma

Conclusion: In this study, we present a therapeutic approach by using DTX that supports the potential usefulness of personalized medicine in vitro and demonstrates it clinically. (Source: Hepatology Research)

top  

  A Phase II Randomized Crossover Study of Liposomal Doxorubicin Versus Weekly Docetaxel in the First-line Treatment of Women With Metastatic Breast Cancer

Metastatic breast cancer first-line treatments with varying dosing frequencies are compared for efficacy and toxicity. Is one regimen superior? Clinical Breast Cancer (Source: Medscape Hematology-Oncology Headlines)

top  

  Achievements and unmet needs in the management of advanced ovarian cancer.

Authors: Guarneri V, Piacentini F, Barbieri E, Conte PF Ovarian cancer is the second most common gynaecological malignancy, and represents the leading cause of gynecologic cancer-related death in Europe and United States. The majority of the cases are in fact diagnosed in advanced stage, with limited chance to be cured. Optimal management of advanced ovarian cancer includes histopathological diagnosis, accurate surgical staging, debulking surgery and platinum-based chemotherapy. The combination of carboplatin and paclitaxel is commonly recognised as the standard regimen because of tolerability and activity. Intraperitoneal chemotherapy provides superior efficacy results, but its use is still controversial because of poor tolerability and compliance. Unfortunately, despite its chemosens...

top  

  A phase II study of doxifluridine and docetaxel combination chemotherapy for advanced or recurrent gastric cancer

Conclusion  The combination chemotherapy of doxifluridine and docetaxel was well tolerated and relatively effective when used as a second-line chemotherapy for advanced or recurrent gastric cancer. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10120-009-0528-5Authors Takaki Yoshikawa, Kanagawa Cancer Center Department of Gastrointestinal Surgery 1-1-2 Nakao, Asahi-ku Yokohama 241-0815 JapanAkira Tsuburaya, Kanagawa Cancer Center Department of Gastrointestinal Surgery 1-1-2 Nakao, Asahi-ku Yokohama 241-0815 JapanKen Shimada, Showa University Northern Yokohama Hospital Department of Internal Medicine Yokohama JapanAtsushi Sato, Showa University Hospital Department of Medical Oncology Tokyo JapanMakoto Takahashi, Kamishirane Hospital Department of Surge...

top  

  Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB.

Authors: Kim SM, Lee SY, Cho JS, Son SM, Choi SS, Yun YP, Yoon DY, Oh KW, Han SB, Hong JT Ginsenoside Rg3 has been interested for using as a cancer preventive or therapeutic agent. Nuclear Factor-kappa (NF-kappaB) is constitutively activated in the prostate cancer, and gives cancer cells resistance to chemotherapeutic agents. To investigate whether Rg3 can suppress the activation of NF-kappaB, and thus increase susceptibility of prostate (LNCaP and PC-3, DU145) cells against chemotherapeutics, Prostate cancer cell growth as well as activation of NF-kappaB were examined. We found that the combination treatment of Rg3 (50muM) with conventional agent docetaxel (5nM) was more effective in the inhibition of prostate cancer cell growth and induction of apoptosis as well as G(0)/G(1) arrest a...

top  

  Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel.

Authors: Koolen SL, Beijnen JH, Schellens JH Oral administration of the taxanes docetaxel and paclitaxel is hampered by their affinity for drug transporters, especially ABCB1 (P-glycoprotein, Pgp); extensive first-pass metabolism by cytochrome P450 3A (CYP3A); and poor drug solubility. Preclinical studies in Pgp-deficient and wild-type mice demonstrated that modulation of either Pgp or CYP3A resulted in high systemic exposure to docetaxel or paclitaxel. This concept could successfully be translated to clinical trials. PMID: 19924122 [PubMed - indexed for MEDLINE] (Source: Clinical Pharmacology and Therapeutics)

top  

  Concurrent chemoradiation therapy with docetaxel/cisplatin followed by docetaxel consolidation therapy in inoperable stage IIIA/B non-small-cell lung cancer: results of a phase I study.

CONCLUSION: The MTD of DCT after concurrent cisplatin/docetaxel CRT was determined to be 60 mg/m2, but toxicity was considerable. The benefit-risk ratio of DCT has, however, been questioned by a placebo-controlled phase III trial. Further phase III trials need to consider further stratification factors (pretreatment forced expiratory volume [FEV]1, hemoglobin, performance, and stage) to define a role for DCT in patients with NSCLC. PMID: 20085867 [PubMed - in process] (Source: Clinical Lung Cancer)

top  

  Vitamin D: Considerations in the Continued Development as an Agent for Cancer Prevention and Therapy.

Authors: Trump DL, Deeb KK, Johnson CS Considerable preclinical and epidemiologic data suggest that vitamin D may play a role in the pathogenesis, progression, and therapy for cancer. Numerous epidemiologic studies support the hypothesis that individuals with lower serum vitamin D levels have a higher risk of a number of cancers. Measures of vitamin D level in such studies include both surrogate estimates of vitamin D level (residence in more northern latitudes, history of activity, and sun exposure) as well as measured serum 25(OH) cholecalciferol levels. Perhaps, the most robust of these epidemiologic studies is that of Giovannucci et al, who developed and validated an estimate of serum 25(OH) cholecalciferol level and reported that among >40,000 individuals in the Health Professi...

top  

  Antineoplastic Chemotherapy Induced QTc Prolongation.

Authors: Bagnes C, Panchuk PN, Recondo G Anticancer drugs are sometimes associated with QT prolongation. Classical, new and candidate agents to treat cancer may affect ventricular repolarization through a set of different mechanisms. Interference on human ether-a-go-go-related gene potassium ion channels (HERG K+) seems to be a common mechanism for many of these drugs. Anthracycline chemotherapy is associated with electrocardiographic alterations including prolongation of QT interval, development of ventricular late potentials and various arrhythmias. The effects of the interaction of anthracyclines with the monoclonal antibody against HER2/neu (Erb-2) trastuzumab could potentiate the cardiotoxic effects. Electrocardiographic changes have been also reported with the use of 5-fluorourac...

top  

  Docetaxel in Combination with Prednisolone for Hormone Refractory Prostate Cancer

Conclusions The combination of docetaxel 75 mg/m2 every 3 weeks and prednisolone 10 mg daily was effective and well tolerated in Japanese patients with HRPC. The results of this study suggest that a decision concerning discontinuation of this treatment should be carefully considered because a transient PSA rise was observed. Although interstitial pneumonia was rare, the potential risk of its development should be taken into consideration. (Source: Japanese Journal of Clinical Oncology)

top  

  Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer

Recurrent prostate cancer can be osseous, androgen independent and lethal. The purpose is to discern the efficacy of synthetic small molecule telomerase enzyme inhibitors (TEI) alone or in combination with other cytotoxic therapies in controlling metastatic osseous prostate cancer.C4-2B was pre-treated with a match or mismatch TEI for 6 weeks and then inoculated into nude mice subcutaneously or intraosseously. In a separate experiment, untreated C4-2B was injected into femur of nude mice. The mice were divided into seven systemic "combination" treatment groups of control, Ad-BSP-E1a virus, docetaxel, mismatch and match TEI. Serum PSA was followed longitudinally. Histology analyses and histomorphometry were performed. Repeated measure analysis was applied for statistical analysis and Bonfer...

top  

  Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study

Conclusions  Oral sunitinib 37.5 mg/day on Schedule 2/1 with docetaxel 75 mg/m2 IV q21d is a clinically feasible regimen with a manageable safety profile, no pharmacokinetic drug–drug interactions, and shows antitumor activity in patients with advanced solid tumors. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1209-0Authors Francisco Robert, University of Alabama at Birmingham, Comprehensive Cancer Center Birmingham AL USAAlan Sandler, Oregon Health & Science University Portland OR USAJoan H. Schiller, University of Texas Southwestern, Division of Hematology and Oncology Dallas TX USAGlenn Liu, University of Wisconsin Carbone Cancer Center Madison WI USAKaren Harper, University of Alabama at Birmingham, Comprehensive Cancer Cen...

top  

  Sphingosine-1-phosphate: a potential therapeutic agent against human breast cancer

Summary  Sphingosine-1-phosphate (S1P) is an important regulator of cancer development and progression. Its cellular concentration is controlled predominantly by sphingosine kinase (SK) and sphingosine-1-phosphate lyase (SPL). In the current study we showed that mRNA expressions for both SK and SPL were up-regulated throughout all four disease stages in human breast cancer patients. Exogenous administration of S1P produced a bell-shaped dose response for apoptosis in normal mammary gland MCF12A cells but a sigmoid-shaped apoptotic response in breast cancer MCF7 cells. Co-administration of S1P enhanced the cytotoxicity of anticancer drug docetaxel against MCF7 cells. Content Type Journal ArticleCategory SHORT REPORTDOI 10.1007/s10637-009-9375-9Authors Binbing Ling, Unive...

top  

  PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line

Conclusion  Our results indicate that several anticancer drugs can activate PXR-mediated induction of Pgp and affect the accumulation of Pgp substrates. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1221-4Authors Stefan Harmsen, Utrecht University Division of Biomedical Analysis, Department of Pharmaceutical Sciences, Faculty of Science Sorbonnelaan 16 3584 CA Utrecht The NetherlandsI. Meijerman, Utrecht University Division of Biomedical Analysis, Department of Pharmaceutical Sciences, Faculty of Science Sorbonnelaan 16 3584 CA Utrecht The NetherlandsC. L. Febus, Utrecht University Division of Biomedical Analysis, Department of Pharmaceutical Sciences, Faculty of Science Sorbonnelaan 16 3584 CA Utrecht The NetherlandsR. F. Maas-Bakker, Utre...

top  

  Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer

Conclusions  DCS combination chemotherapy is highly active against unresectable metastatic gastric cancer and can be given safely with proper management of adverse events. Further studies of this combination are warranted. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1215-2Authors Yasushi Sato, Sapporo Medical University Fourth Department of Internal Medicine, School of Medicine South 1 West 16, Chuo-ku Sapporo 060-8543 JapanTetsuji Takayama, Tokushima University Department of Gastroenterology and Oncology Tokushima JapanTamotsu Sagawa, Sapporo Medical University Fourth Department of Internal Medicine, School of Medicine South 1 West 16, Chuo-ku Sapporo 060-8543 JapanYasuo Takahashi, Hokkaido Cancer Center Department of Gastroenterology Sa...

top  

  Neoadjuvant Chemotherapy Shows Similar Response in Patients With Inflammatory or Locally Advanced Breast Cancer When Compared With Operable Breast Cancer: A Secondary Analysis of the GeparTrio Trial Data [Breast Cancer]

Conclusion No evidence of a difference in response to neoadjuvant chemotherapy was found by tumor stage when analysis was adjusted for baseline characteristics. (Source: Journal of Clinical Oncology)

top  

  Pulmonary toxicity in patients receiving docetaxel chemotherapy

Abstract  Pulmonary toxicity can rarely be seen with cytotoxic agents. We aimed at investigating the pulmonary toxicity of docetaxel in patients other than lung carcinoma. Forty patients were investigated prospectively. Spirometry, DLCO and high-resolution computed tomography (HRCT) scans were applied to all patients before and 14–21 days after completion of docetaxel. We used a HRCT scoring system that was based on the previous studies. We have seen no pulmonary symptoms that may reflect pulmonary toxicity. There were statistically significant differences between pre- and post-treatment values of FEV1 (L/s), FEV1/FVC (%), DLCO/VA (DLCO/L), DLCO/VA (%) (P < 0.05), FEF25–75 (L/s), FEF25–75 (%) (P < 0.01), DLCO (mL/mmHg/min), DLCO (%) (P&nb...

top  

  Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck

Abstract  We compared concurrent chemoradiotherapy (CCRT) with docetaxel, cisplatin (CDDP), and 5-fluorouracil (5-FU) (TPF) with CCRT with CDDP, 5-FU, methotrexate and leucovorin (PFML) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) in terms of safety and efficacy on survival. A total of 100 patients were enrolled. The TPF group received CCRT with the TPF regimen [docetaxel (50 mg/m2: day 1), CDDP (60 mg/m2: day 4), and continuous 5-FU infusion (600 mg/m2/day: days 1–5)]. In the PFML group, patients received CCRT with the PFML regimen [CDDP (60 mg/m2: day 4)], continuous 5-FU infusion (600 mg/m2/day: days 1–5), methotrexate (30 mg/m2: day 1) and leucovorin (20 mg/m2/day: days 1–5)]. Both groups re...

top  

  Editorial Comment

The authors ought to be commended for their diligent follow-up and assessment of long-term outcomes from their original phase I study of docetaxel in patients who were refractory to most other intravesical therapies. Although it is difficult to resist the temptation to assess and report “response” from phase I studies, one has to be cautious about doing so. These data substantiate earlier observations with other chemotherapeutic agents used intravesically in the BCG refractory setting, such as valrubicin and gemcitabine. Initially, chemotherapy appears to yield an admirable response rate as seen with gemcitabine and with docetaxel. However, the response does not appear to be durable. The relatively poor long-term success of single agent intravesical chemotherapy has a familiar ring to ...

top  

  c-Jun-NH2-kinase-1 Inhibition Leads to Antitumor Activity in Ovarian Cancer.

CONCLUSIONS: These studies identify JNK-1 as an attractive therapeutic target in ovarian carcinoma and that the redesigned WBZ_4 compound should be considered for further clinical development. Clin Cancer Res; 16(1); 184-94. PMID: 20028751 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)

top  

  Association of Epidermal Growth Factor Receptor Polymorphism, Skin Toxicity, and Outcome in Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab-Docetaxel Treatment.

CONCLUSIONS: Our study revealed an influence of the EGFR-R521K genotype on skin toxicity and suggested its relation to clinical activity of cetuximab/docetaxel treatment. Clin Cancer Res; 16(1); 304-10. PMID: 20028750 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)

top  

  Gefitinib improved survival vs. cisplatin/docetaxel in patients with NSCLC, EGFR mutations

(Source: HemOncToday.com)

top  

  Gefitinib versus cisplatin plus docetaxel in patients with NSCLC harbouring EGFR mutations

This study (WJTOG3405), conducted in Japan, recruited 177 patients aged ?75 years with advanced (stage IIIB/IV) or ... (Source: NeLM - Oncology)

top  

  The effects of mixed MPEG-PLA/Pluronic((R)) copolymer micelles on the bioavailability and multidrug resistance of docetaxel.

This study presents not only a new micelle structure for a diblock-triblock copolymer system, but also a method for enhanced bioavailability of docetaxel and to overcome some of the limitations on its multidrug resistance in cancer therapy. PMID: 20031202 [PubMed - as supplied by publisher] (Source: Biomaterials)

top  

  A Retrospective Analysis of Erlotinib and TP/GP Regimen in the Treatment of Advanced Non-small Cell Lung Cancer

Conclusion Erlotinib on advanced non-small cell lung cancer shows more effectiveness and adverse reactions are tolerable. The further clinical study should be warranted. (Source: Chinese Journal of Lung Cancer)

top  

  [Application of neoadjuvant chemotherapy for operable breast cancer.]

CONCLUSION: Neoadjuvant chemotherapy can enhance the breast conservation rate, lower the clinical staging of the tumors and minimize the surgery area to improve the postoperative quality of life of the patients. PMID: 20034916 [PubMed - as supplied by publisher] (Source: Journal of Southern Medical University)

top  

  Perivascular carotid inflammation: an unusual case of carotidynia

Abstract  A 59-year-old woman was admitted to the hospital with a fever and rigors for 2 days. She was on chemotherapy (docetaxel, carboplatin, and trastuzumab) for her stage II invasive ductal carcinoma of the breast. Her physical exam was unremarkable except for the fever. The white blood cells were 21,200/mm3 with 92% of neutrophils. ESR was 106 mm/h. An extensive infectious workup was negative. On day 6, while still febrile, the patient complained of a left-sided neck pain. She exhibited tenderness over the left carotid artery. A CT scan of the neck without intravenous contrast showed perivascular inflammation of the left common carotid artery, without evidence of a collection, arterial thrombosis, aneurysm, or dissection. The etiology of this finding was possibly c...

top  

  beta-Tubulin III mRNA expression and docetaxel sensitivity in non-small cell lung cancer.

CONCLUSION: Our results demonstrated that beta-tubulin III mRNA expression level in malignant effusions, in which all cancer cells were metastatic, was correlated with docetaxel sensitivity in NSCLC. This highlights the potential role of biomarkers in malignant effusions in further customized chemotherapy. PMID: 20003833 [PubMed - in process] (Source: Clinical and Investigative Medicine)

top  

  [New drugs in metastatic castration-resistant prostate cancer.]

Authors: Albiges L, Loriot Y, Gross-Goupil M, de La Motte Rouge T, Blesius A, Escudier B, Massard C, Fizazi K Despite that greater knowledge of prostate cancer biology has led to the isolation of many new and promising targets, treatment of metastatic prostate cancer is still challenging. New agents targeting these molecules are currently under development in large randomized phase III trials, to improve overall survival and the quality of life of patients with metastatic castrate-resistant prostatic cancer (CRPC). Cytotoxic chemotherapy (docetaxel-based chemotherapy) demonstrated clinical benefit on overall survival, but could be improved. Drugs targeting directly or not the androgen receptor such as abiraterone or new specific peripheral anti-androgens (MDV3100) are very promising. B...

top  

  {beta}-Tubulin-II Expression Strongly Predicts Outcome in Patients Receiving Induction Chemotherapy for Locally Advanced Squamous Carcinoma of the Head and Neck: A Companion Analysis of the TAX 324 Trial [Head and Neck Cancer]

Conclusion Increased tumor expression of βT-II is strongly associated with adverse outcome in LASCCHN patients treated with IC, and our data suggest low expression of βT-II may predict patients most likely to benefit from induction TPF therapy. Further, simple models which combine expression of βT-II with a carefully defined set of additional immunohistochemical markers may have significant prognostic impact for patients with LASCCHN. (Source: Journal of Clinical Oncology)

top  

  American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer [ASCO SPECIAL ARTICLE]

The purpose of this article is to provide updated recommendations for the treatment of patients with stage IV non–small-cell lung cancer. A literature search identified relevant randomized trials published since 2002. The scope of the guideline was narrowed to chemotherapy and biologic therapy. An Update Committee reviewed the literature and made updated recommendations. One hundred sixty-two publications met the inclusion criteria. Recommendations were based on treatment strategies that improve overall survival. Treatments that improve only progression-free survival prompted scrutiny of toxicity and quality of life. For first-line therapy in patients with performance status of 0 or 1, a platinum-based two-drug combination of cytotoxic drugs is recommended. Nonplatinum cytotoxic doub...

top  

  Trastuzumab for Patients With Axillary-Node-Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial [Breast Cancer]

Conclusion After a 47-month median follow-up, 1 year of trastuzumab given sequentially after adjuvant chemotherapy was not associated with a statistically significant decrease in the risk of relapse. (Source: Journal of Clinical Oncology)

top  

  Longitudinal evaluation of vitamin D plasma levels during anthracycline- and docetaxel-based adjuvant chemotherapy in early-stage breast cancer patients

(Source: Annals of Oncology)

top  

  Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer

Conclusions: The DE and DC regimens have similar efficacy but different toxicity. Either regimen can be used as front-line treatment of ABC. (Source: Annals of Oncology)

top  

  Development of a new G-CSF product based on biosimilarity assessment.

CONCLUSION: The results of these studies demonstrate the biosimilarity of Zarzio(R) with its reference product Neupogen(R). PMID: 20019087 [PubMed - as supplied by publisher] (Source: Ann Oncol)

top  

  Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis.

CONCLUSIONS: Even though the combination VC has similar effectiveness compared with DG in patients with metastatic lung cancer, it is associated with a lower overall treatment cost and hence, it is preferable from an economic perspective. However, it should be noted that although VC is associated with lower cost, it is also more toxic than DG regimen, a significant parameter that should be considered in clinical decisions. PMID: 20019086 [PubMed - as supplied by publisher] (Source: Ann Oncol)

top  

  Docetaxel: Nail disorders treated with meloxicam: case report

(Source: Reactions)

top  

  Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance

Conclusion  Paclitaxel combined with ifosfamide was effective and tolerable in anthracycline-/docetaxel-pretreated MBC. Overcoming docetaxel resistance by using paclitaxel in combination with ifosfamide needs to be addressed through further investigation. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1176-5Authors Yong Wha Moon, Yonsei University College of Medicine Department of Internal Medicine, Yonsei Cancer Center 250 Seongsanno, Seodaemun-gu Seoul 120-752 KoreaJoo Hyuk Sohn, Yonsei University College of Medicine Department of Internal Medicine, Yonsei Cancer Center 250 Seongsanno, Seodaemun-gu Seoul 120-752 KoreaHye Jin Choi, Yonsei University College of Medicine Department of Internal Medicine, Yonsei Cancer Center 250 Seongsanno, Se...

top  

  AVADO: Adding Bevacizumab to Docetaxel in First-line Treatment of Advanced Breast Cancer Improves PFS but Not OS

Capsule Summary - In results from the phase III AVADO study, the addition of bevacizumab to docetaxel as first-line therapy did not improve OS in patients with recurrent or metastatic breast cancer (Source: Clinical Care Options Oncology - Breast Cancer)

top  

  Conference report: Bevacizumab added to chemotherapy in advanced breast cancer improves progression-free survival?

Source: BioSpace Area: News According to findings from the Phase III RIBBON 2 study, presented at the 32nd Annual San Antonio Breast Cancer Symposium, the addition of bevacizumab to chemotherapy in the second-line treatment of women with advanced HER2-negative breast cancer improves progression-free survival (PFS).   RIBBON 2 is an international, multicenter, randomized, double-blind, placebo-controlled clinical study of 684 patients with metastatic HER2-negative breast cancer who had previously received chemotherapy alone for metastatic disease. The trial evaluated the combination of either bevacizumab or placebo with an investigator's choice of chemotherapy, including taxanes (paclitaxel, protein-bound paclitaxel or docetaxel), gemcitabine, capecitabine or vinorelbine. Dependin...

top  

Top Viagra Store

A first shop in the series of one-pill shops is rightfully viagra-targeted. The index page offers only Viagra, both generic and original.It is possible to purchase other ED products from other pagers, but the main accent is on Viagra.

top-viagra-store.com

Indian Meds

A most recent indian-themed, ethnic site. Includes generic and original (brand) products. al our standard navigational tools and support options are available. This site converts nicely on general pharmaceutical traffic as it has products for vurtually any need.

indianmeds.org

Friendly ED Pharmacy

Many ED customers are anxious about the status their orders. This special friendly site is here to solve the problem. "State of the art" design features high usability and clearly visible support options. All this helps to satisfy even the most demanding customer and results in increased sales ratio.

friendly-ed-pharmacy.com

Popular ED Products

This ED site offers simplistic design that gets right to the point - this IS the site for ED. Popular ED list the top selling products and converts best on ED-targeted, pill-specific traffic.

popular-ed-products.com

Perfect ED Store

This site is just right for ED customers. All ED products are conveniently listed at main page, allowing to make an easy choice. Our regular Sample Pills Offer is emphasized here. Customers can try new products and are likely to return for more refills.

perfect-ed-store.com

Worlds Best Pharmacy

The name says it all. This is the best online pharmacy on the web. The index page is set to show the most polular ED products, while the menu and quicksearch allow to find products in other categories.

worlds-best-pharmacy.com

Delhi Drugs

This Indian-themed site offers a completely new design. All our generic products are availabe and can easily be located with the help of quicksearch feature. Includes our latest shopping engine and billing page.

www.delhi-drugs.com

Indian Generics

Many customers are looking for Indian drugs, and this site is designed specifically for such customers. It includes many generic products, modern design, translated into 7 languages and prices in both USD and Euros. Also it uses our latest shopping engine and billing page.

www.indian-generics.com